2
2
0
2

t
c
O
0
1

]
E
S
.
s
c
[

3
v
9
7
4
6
0
.
8
0
2
2
:
v
i
X
r
a

Design and Validation of an Open-Source Closed-Loop Testbed
for Artificial Pancreas Systems

Xugui Zhou
xugui@virginia.edu
University of Virginia
Charlottesville, Virginia, USA

Haotian Ren
hr3xw@virginia.edu
University of Virginia
Charlottesville, Virginia, USA

Maxfield Kouzel
mak3zaa@virginia.edu
University of Virginia
Charlottesville, Virginia, USA

Homa Alemzadeh
ha4d@virginia.edu
University of Virginia
Charlottesville, Virginia, USA

ABSTRACT
The development of fully autonomous artificial pancreas systems
(APS) that independently regulate the glucose levels of patients
with Type 1 diabetes has been a long-standing goal of diabetes
research. A significant barrier to progress is the difficulty of testing
new control algorithms and safety features, since clinical trials are
time- and resource-intensive. To facilitate ease of validation, we
propose an open-source APS testbed that can integrate state-of-
the-art APS controllers and glucose simulators with a novel fault
injection engine. The testbed is used to reproduce the blood glucose
trajectories of real patients from a clinical trial conducted over six
months. We evaluate the performance of two closed-loop control
algorithms (OpenAPS and Basal Bolus) using the testbed and find
that these control algorithms are able to keep blood glucose in a
safe region 93.49% and 79.46% of the time on average, compared
with 66.18% of the time for the clinical trial. The fault injection
engine simulates the real recalls and adverse events reported to
the U.S. Food and Drug Administration (FDA) and demonstrates
the resilience of the controller in hazardous conditions. We use
the testbed to generate 2.5 years of synthetic data representing
20 different patient profiles with realistic adverse event scenarios,
which would have been expensive and risky to collect in a clinical
trial.

CCS CONCEPTS
â€¢ Computer systems organization â†’ Embedded and cyber-
physical systems; Dependable and fault-tolerant systems and
networks; â€¢ Applied computing â†’ Life and medical sciences.

KEYWORDS
Validity Assessment, Artificial Pancreas System, Testbed, Adverse
Event, Safety, Glucose Simulation, Diabetes

Permission to make digital or hard copies of part or all of this work for personal or
classroom use is granted without fee provided that copies are not made or distributed
for profit or commercial advantage and that copies bear this notice and the full citation
on the first page. Copyrights for third-party components of this work must be honored.
For all other uses, contact the owner/author(s).
CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA
Â© 2022 Copyright held by the owner/author(s).
ACM ISBN 978-1-4503-9476-5/22/11.
https://doi.org/10.1145/3551455.3559151

1

ACM Reference Format:
Xugui Zhou, Maxfield Kouzel, Haotian Ren, and Homa Alemzadeh. 2022.
Design and Validation of an Open-Source Closed-Loop Testbed for Artifi-
cial Pancreas Systems. In ACM/IEEE International Conference on Connected
Health: Applications, Systems and Engineering Technologies (CHASEâ€™ 22),
November 17â€“19, 2022, Washington, DC, USA. ACM, New York, NY, USA,
12 pages. https://doi.org/10.1145/3551455.3559151

1 INTRODUCTION
Medical cyber-physical systems (MCPS) apply computational al-
gorithms to regulate and control complex processes in the human
body. By nature, these are safety-critical systems that directly affect
the health of those who use them, so safety assurance is crucial.
Developing high-fidelity simulators that can capture a variety of pa-
tient profiles and physiological dynamics as well as react to changes
in environment and activity is very important, as it allows consid-
erable research on the safety assurance of MCPS to be performed
at an accelerated rate while avoiding unnecessary risks to patients.
Another essential need is the ability to simulate unexpected events
such as accidental faults, human errors, and attacks that lead to
adverse events. Such closed-loop testbeds can enable verification
of control algorithms and safety features before the additional cost
of clinical trials and reduce the possibility of harm to patients.

Progress has been made in developing these closed-loop testbeds
in many vital areas of MCPS, such as a virtual heart model for pace-
maker verification [73], simulation platforms for robot-assisted
surgery [21, 22], and joint simulation of the cardiovascular system
and pharmacokinetic interactions [8, 18]. Further, validation for not
just medical controllers but also medical protocols for treatment
such as cardiac arrest [37] has proven effective at verifying experi-
mental treatments before it ever reaches actual patients. However,
few closed-loop testbeds for artificial pancreas systems (APS) are
found in the literature [68, 69], not considering variety of patient
profiles and adverse event scenarios.

The APS is a good example of a promising MCPS that the U.S.
Food and Drug Administration (FDA) approved through clinical
trials. Much work has been done in the literature to develop realistic
diabetes simulators [12, 42, 45], design advanced control algorithms
to maintain glucose concentration at healthy levels [4, 63], and con-
duct large-scale clinical trials [15, 32, 43]. However, to the best of
our knowledge, none of these works considered closed-loop inte-
gration of simulators, controllers, and safety mechanisms or the
simulation of adverse events. Control software must be tested in

 
 
 
 
 
 
CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

X. Zhou, M. Kouzel, H. Ren, H. Alemzadeh.

a broad spectrum of environments and with a variety of patient
profiles and physiological dynamics in order to be fully verified.
However, it is challenging to identify and tune simulator parameters
that characterize the patient profiles and physiological dynamics
(e.g., meals and physical activity) and generate realistic and repre-
sentative adverse event scenarios.

To fill this gap, this paper presents the design and validation
of an open-source, closed-loop testbed for APS that can integrate
state-of-the-art Type 1 diabetes glucose simulators (e.g., Glucosym
[66] or UVA-Padova [12]) and insulin delivery control software
(e.g., OpenAPS or Basal-Bolus) together with an adverse events
simulator that simulates the typical adverse events reported to the
FDA. We assess the validity of the proposed testbed by comparing
the simulator outputs, controller outputs, and closed-loop outcomes
with the data collected from a clinical trial. An optimization method
is also proposed to reconstruct the blood glucose (BG) traces from
a real-world clinical trial by estimating the patient profiles.

Experimental results show that the integrated glucose simulators
can well reproduce the BG traces in the clinical trial, given the
exact insulin dosages in the trial, and the integrated (open-loop)
controllers keep a low mean squared error with the actual pump
outputs in the clinical trial. The closed-loop simulations can keep
blood glucose in a safe region 93.49% and 79.46% of the time on
average, compared with 66.18% of the time for the clinical trial.
Because the testbed aims to provide a platform to validate different
control algorithms and safety features efficiently, we provide an
easy-to-use fault injection implementation for both simulators and
detail how the simulated faults compare to real fault scenarios in
the device recalls and adverse events reported to the FDA.
The main contributions of the paper are as follows:

â€¢ Proposing an open-source closed-loop platform by integrating
classical artificial pancreas (AP) controllers (OpenAPS and Basal-
Bolus) and glucose simulators (Glucosym and UVA-Padova), which
(1) enables experimental evaluation of different controllers, pre-
diction algorithms, and pump functionalities, or other studies on
APS that do not have access to clinical patients; (2) integrates a
fault injection engine to simulate potential safety and security
issues and adverse events in APS caused by accidental software
and hardware faults, human errors, or malicious attacks.

â€¢ Developing an optimization method to estimate patient profiles
and reconstruct BG trajectories from clinical studies in simula-
tion, which extends the number of virtual patients in the testbed
and enables the assessment of different algorithms and adverse
event scenarios using existing patient datasets without the need
for doing new clinical trials for each algorithm.

â€¢ Simulating example adverse event scenarios involving APS based
on the data reported to the FDA, resulting in the generation of
2.5 years of synthetic data with different adverse event scenarios
for 20 different patient profiles, which would have been very
expensive and risky to collect from real patients or clinical trials.
â€¢ Assessing the validity of the APS testbed based on a publicly-
available clinical trial dataset that includes six months of data for
168 diabetic patients. The results show that the APS simulators
and controllers can reasonably approximate the actual glucose
monitor and insulin pump functionalities with an average mean
squared error of 3.97ğ‘¥10âˆ’3. Also, the closed-loop simulations

2

Figure 1: Artificial Pancreas System
show that the integrated OpenAPS and Basal-Bolus controllers
can keep the blood glucose in the target range for at least 11.28%
longer time than the controllers used in clinical trials.

2 BACKGROUND
Artificial Pancreas System (APS): APS is a medical control sys-
tem that regulates the glucose levels of people with Type 1 diabetes
[3], who cannot regulate their own glucose levels because their
pancreas does not produce insulin on its own. An APS is responsi-
ble for regulating Blood Glucose (BG) dynamics by monitoring BG
concentration in the patientâ€™s body through sensor data collected
from a Continuous Glucose Monitor (CGM) and by providing in-
sulin at the correct rate to the patient through an insulin pump. The
control software estimates the current patient status (e.g., glucose
value, insulin on board (IOB)) and calculates the next recommended
insulin rate value to be delivered to the patient. The typical APS is
shown in Fig. 1.

The development of a fully autonomous artificial pancreas sys-
tem has been a long-standing goal of research into Type 1 diabetes.
A milestone was reached when the first commercially available
closed-loop APS that automated basal insulin delivery was approved
by the FDA in 2017 [67]. Nevertheless, it still required user input
to indicate insulin boluses. An ideal controller must be able to ac-
count for unannounced meals and variety of physical activities.
While there are existing algorithms for the detection of meals and
different activities [46], they have yet to be incorporated into APS
controllers.

APS Simulation: The APS controllers and glucose simulators
are fundamentally built on the patient models that reflect how the
body reacts to insulin dosage. Two main patient models available
in the literature that we use in this paper are Glucosym and UVA-
Padova. These simulators use systems of differential equations to
model the change of state variables important to glucose and insulin
kinetics. The equations have a large number of parameters, and
each patient, real or virtual, has a unique set of values for these
parameters, referred to as their patient profile.

The information flow of the APS simulation follows that of the
real APS (see Fig. 1 and Fig. 2). The patient model receives in-
sulin dosage from the controller through the insulin pump, and
the controller receives BG data through the CGM. Different con-
trol algorithms can be implemented without affecting the flow of
information to and from the patient model.

Improved control algorithms have driven recent advances in APS
performance. Traditional control algorithms such as proportional
integral derivative (PID) [60], model predictive control (MPC) [28],
and fuzzy logic [40] have given way to machine learning based tech-
niques such as deep neural networks [14, 38] and reinforcement

Design and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

Table 1: Recalls and Adverse Events of APS Devices (2012âˆ’2021)

APS Component
Glucose Monitors
Insulin Pumps

No. Recalls No. Products No. Adverse Events
48
44

5.25 million
2.45 million

1.62 million
1.11 million

learning [6, 76], which offer more powerful insights into relation-
ships in sensor data. However, machine learning techniques are
far more intractable than traditional algorithms, so they must be
rigorously tested before deployment to ensure the ML controller
performs accurately in any possible scenario. This gives rise to a
particular need for comprehensive testbeds in APS.

Safety of APS: A shortcoming of current testbeds is a lack of in-
clusion of adverse events that happen rarely and outside of standard
system behavior. Safety-critical medical devices such as APS are
often worn by or implanted in the patients, requiring them to oper-
ate on wireless networks and within unpredictable environments
and activity settings, which naturally leads to safety concerns. For
example, a smartphone app was recently developed for APS to re-
motely interface with CGM and insulin pump devices [44]. Several
past studies have shown that medical devices (e.g., patient monitors,
infusion pumps, implantable pacemakers, and tele-operated surgi-
cal robots) are vulnerable to accidental faults or malicious attacks
with potential adverse impacts on patients [20, 23, 24, 49, 74, 75].
In APS, accidental faults or malicious attacks might happen in
any of the system components [13], including the CGM [9], insulin
pump [64], or the APS controller [34]. Since a variety of CGMs
and insulin pumps are currently available in commercial diabetes
management systems [39], large amounts of real-world data on
faults and security vulnerabilities that led to recalls and adverse
events are available from the public databases for analysis and sim-
ulation. We searched the FDA recalls [57] and manufacturer and
user facility device experience (MAUDE) databases [53] for safety
issues related to APS during the last ten years. As shown in Table 1,
over this period, millions of APS devices were recalled globally, and
millions of adverse events (involving device malfunctions, patient
injuries, or deaths) were reported by diabetic patients, healthcare
professionals, and device manufacturers. This indicates an urgent
need to investigate and improve the safety and dependability of APS
devices. Note that a single recall event corresponding to a software
or hardware defect might lead to the removal or upgrade/repair of
all the devices on the market with that software or hardware com-
ponent. Also, the root causes of adverse events cannot be concluded
solely based on the number of reports and the limited information
available in the public FDA databases [53].

Previous clinical trial studies have also shown the occurrence
of adverse events due to pump infusion set failures, characterized
by patterns of increasing glucose values despite increased insulin
infusion [31]. Examples of adverse events with the risk of harm
to patients are severe hypoglycemia, diabetic ketoacidosis (serum
glucose > 250 ğ‘šğ‘”/ğ‘‘ğ¿ [72]), serious events related to the device,
hyperglycemia or ketosis without diabetic ketoacidosis [43].

3 DESIGN OF CLOSED-LOOP APS TESTBED
The overall structure of the open-source closed-loop Artificial Pan-
creas System (APS) testbed is shown in Fig. 2. The APS testbed
includes two state-of-the-art glucose simulators (Glucosym simula-
tor [66] and the UVA-Padova Type 1 Diabetes simulator [12]) and

Figure 2: Overall Structure of the Closed-loop APS Testbed

two control software (OpenAPS and Basal-Bolus), together with
40 virtual patients. The simulator can run with the integrated vir-
tual patient library or by loading actual patient profiles. Similarly,
the testbed also includes an extending interface to the controllers
that can load external control algorithms to help improve or eval-
uate the controllers in commercial insulin pumps. Note that only
one simulator and controller are selected to run the closed-loop
simulation. We also design an adverse event simulator that can
emulate common adverse events in APS, including hypoglycemic
events, hyperglycemic events, diabetic ketoacidosis, or other device
malfunctions (e.g., in CGM sensors, insulin pumps, or controllers),
by injecting faults into the input/output of the control software at
compile time.

The proposed closed-loop APS testbed and generated data traces
are made publicly available to the research community1. The testbed
is implemented with Python programming language at the appli-
cation level, and can be installed on a Ubuntu operating system
(16.04 LTS at least) automatically with an auto-script. This testbed
offers a platform for other researchers to evaluate the performance
of different control algorithms, validate the efficiency or safety of
insulin delivery, develop the safety assurance or monitoring mecha-
nisms for APS, and investigate the application of machine learning
techniques in Type 1 diabetes treatment. The following subsections
present a detailed description of the different components in the
testbed.

3.1 Patient Glucose Simulators
Table 2 shows an overview of the dynamic models used by each
glucose simulator to emulate the effect of insulin dosage on the
body, along with the required parameters for characterizing the
patient profiles to run the simulators.

Glucosym Patient Simulator: The Glucosym simulator is an
open-source human body glucose simulator that was developed
to help build and test automatic insulin delivery systems. This
simulator contains patient models derived from data collected from
10 actual adult patients with Type I diabetes mellitus for 18 Â± 13.5
years aged 42.5 Â± 11.5 years, with their glucose dynamics predicted
using a Medtronic virtual patient (MVP) model [45].

The MVP model includes five components that describe the sub-
cutaneous insulin (ğ¼ğ‘†ğ¶ ) delivery, the plasma insulin concentration

1https://github.com/UVA-DSA/APS_TestBed

3

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

X. Zhou, M. Kouzel, H. Ren, H. Alemzadeh.

Table 2: Summary of Patient Glucose Simulators

Simulator Dynamic Model

Patient
Profiles

Glucosym

Cğ¼ , ğœ 1,
ğœ 2, Vğº ,
p2, ğ¸ğºğ‘ƒ,
ğºğ¸ğ‘ğ¼ , Sğ¼

Medtronic Virtual Patient (MVP) Model:
sub-cutaneous insulin delivery,
the plasma insulin concentration,
the insulin effect,
the glucose kinetics,
and the glucose appearance.
Model of Kovatchev et al. [36]:
plasma concentration,
glucose fluxes,
and insulin fluxes.
* Cğ¼ =Insulin clearance (dL/min).
* ğœ 1, ğœ 2=Time constant associated with insulin movement between

ğ¸ğºğ‘ƒ,
ğ‘ˆğ‘–ğ‘– , ğ‘ˆğ‘–ğ‘‘ ,
ğ‘˜1, ğ‘˜2,
ğºğ‘ğ‘

UVA-
Padova

the SC delivery site and plasma (min).

* Vğº =Distribution volume in which glucose equilibrates (dL).
* p2=Delay in insulin action upon increase in plasma insulin (1/min).
* EGP=Endogenous glucose production rate that would be estimated

at zero insulin (mg/dL/min).

* GEZI=Effect of glucose per se to increase glucose uptake into cells
and lower endogenous glucose production at zero insulin (1/min).

* Sğ¼ =Baseline sensitivity factor (dl/micro Unit).
* ğ‘ˆğ‘–ğ‘– =Insulin-independent glucose utilization.
* ğ‘ˆğ‘–ğ‘‘ =Insulin-dependent glucose utilization.
* ğ‘˜1, ğ‘˜2=Rate parameters of glucose kinetics.
* ğºğ‘ğ‘ =Initial amount of glucose in plasma.

(ğ¼ğ‘ƒ ), the insulin effect (ğ¼ğ¸ğ¹ ğ¹ ) to lower blood glucose, the glucose
kinetics, and the glucose appearance following a meal (ğ‘…ğ´) (see
Eq. 1-5). A three-compartment model [36] was used to identify the
insulin activity after injection to the patient body (see Eq. 1-3). With
the value of glucose appearance given by the two-compartment
model shown in Eq. 5, the Bergman minimal model [1] and Sherwin
model [41] described in Eq.4 were finally used to derive an estima-
tion of the BG value at the next step. These five equations form the
basis of the MVP dynamic model used in the Glucosym simulator
for educating and training individuals with Type 1 diabetes [45]:

ğ‘‘ğ¼ğ‘†ğ¶ (ğ‘¡)
ğ‘‘ğ‘¡
ğ‘‘ğ¼ğ‘ƒ (ğ‘¡)
ğ‘‘ğ‘¡
ğ‘‘ğ¼ğ¸ğ¹ ğ¹ (ğ‘¡)
ğ‘‘ğ‘¡
ğ‘‘ğµğº (ğ‘¡)
ğ‘‘ğ‘¡

(cid:18)

Â·

ğ¼ğ‘†ğ¶ (ğ‘¡) âˆ’

(cid:19)

ğ¼ğ· (ğ‘¡)
ğ¶ğ¼

Â· (ğ¼ğ‘ƒ (ğ‘¡) âˆ’ ğ¼ğ‘†ğ¶ (ğ‘¡))

= âˆ’

= âˆ’

1
ğœ1
1
ğœ2

= âˆ’ğ‘2 Â· (ğ¼ğ¸ğ¹ ğ¹ (ğ‘¡) âˆ’ ğ‘†ğ¼ Â· ğ¼ğ‘ƒ (ğ‘¡))

= âˆ’(ğºğ¸ğ‘ğ¼ + ğ¼ğ¸ğ¹ ğ¹ (ğ‘¡)) Â· ğµğº (ğ‘¡) + ğ¸ğºğ‘ƒ + ğ‘…ğ´ (ğ‘¡)

ğ‘…ğ´ (ğ‘¡) =

ğ¶ğ» (ğ‘¡)
ğ‘‰ğº Â· ğœğ‘š 2

Â· ğ‘¡ Â· ğ‘’âˆ’ 1

ğœğ‘š

(1)

(2)

(3)

(4)

(5)

where, ğºğ¸ğ‘ğ¼, ğ¸ğºğ‘ƒ, ğ‘†ğ¼ , ğ¶ğ¼ , ğ‘2, ğœ1, ğœ2 are patient-specific parame-
ters, with their explanation presented in Table 2. Other parameters,
such as the input information of insulin doses and sampling fre-
quency, are also needed for running the Glucosym simulator. The
full list of input parameters used in this simulator is listed in Table
3. An implementation of this simulator is publicly available at [66].
UVA-Padova simulator: The other simulator we integrated
into the APS testbed is the UVA-Padova Type 1 Diabetes Simulator,
which FDA has approved for pre-clinical testing on animals. In

4

Table 3: Input Parameters of Glucosym Simulator.

Input Description

Insulin dose in units given during the time-step. In the
case of a basal (insulin delivery) adjustment, we need to
calculate how much insulin will be given in the time-step
defined by "dt" (i.e. how many insulin units will be given
in 5 minutes by the set basal profile or temporary basal?).
Change in time each step in minutes.
Current index from the start of the simulation, starting
at 0.
Total simulation run-time in minutes.
The delivery of insulin.

Insulin
Dose

dt

Index

Time
Basal

Events

Events are set so that the simulator will consider them
during the run. The events were sent on-the-go.

this simulator, the model of glucose kinetics is described using the
following equations [12]:

ğ‘‘ğºğ‘ (ğ‘¡)
ğ‘‘ğ‘¡
ğ‘‘ğºğ‘¡ (ğ‘¡)
ğ‘‘ğ‘¡

= ğ¸ğºğ‘ƒ âˆ’ ğ‘ˆğ‘–ğ‘– âˆ’ ğ‘˜1ğºğ‘ (ğ‘¡) + ğ‘˜2ğºğ‘¡ (ğ‘¡) , ğºğ‘ (0) = ğºğ‘ğ‘
ğ‘˜1
ğ‘˜2

= ğ‘ˆğ‘–ğ‘‘ (ğ‘¡) + ğ‘˜1ğºğ‘ (ğ‘¡) âˆ’ ğ‘˜2ğºğ‘¡ (ğ‘¡) , ğºğ‘¡ (0) = ğºğ‘ğ‘

(6)

(7)

where ğºğ‘ (ğ‘¡) represents the amount of glucose in plasma, and ğºğ‘ (ğ‘¡)
describes the amount of glucose in the tissue. The blood glucose
level that the CGM samples is given by Equation 8:

ğº (ğ‘¡) =

ğºğ‘ (ğ‘¡)
ğ‘‰ğ‘”

(8)

The endogenous glucose production rate, ğ¸ğºğ‘ƒ, is modeled as a
function of glucose in plasma, ğºğ‘ (ğ‘¡), and delayed insulin action in
the liver, ğ‘‹ ğ¿ (ğ‘¡), as shown in Equation 9.

ğ¸ğºğ‘ƒ = ğ‘˜ğ‘1 âˆ’ ğ‘˜ğ‘2 Â· ğºğ‘ (ğ‘¡) âˆ’ ğ‘˜ğ‘3 Â· ğ‘‹ ğ¿ (ğ‘¡)
(9)
ğ‘‹ ğ¿ (ğ‘¡) is based on insulin concentration in plasma. The insulin
dose delivered to the patient by the pump, ğ¼ ğ· (ğ‘¡), factors into this
plasma insulin level via the insulin subsystem, which is split into
ğ¼ğ‘˜ (ğ‘¡) and ğ¼ğ‘ ğ‘ (ğ‘¡). ğ¼ğ‘ ğ‘ (ğ‘¡) represents the subcutaneous insulin level,
and is impacted by insulin doses as follows:

ğ‘‘ğ‘‹ ğ¿ (ğ‘¡)
ğ‘‘ğ‘¡

= âˆ’ğ‘˜ğ‘– Â·

(cid:16)
ğ‘‹ ğ¿ (ğ‘¡) âˆ’ ğ‘˜ğ‘ğ‘–ğ¼ğ‘˜ (ğ‘¡) âˆ’ ğ‘˜ğ‘ğ‘–ğ¼ğ‘ ğ‘ (ğ‘¡)

(cid:17)

(10)

Table 4: Input Parameters of UVA-Padova Simulator.

Input
Initial BG
Sensor Settings
Pump Settings
Meals

Profile
Start Time
Seed

Insulin Dose

Description
Starting value for patientâ€™s blood glucose
Type of CGM sensor and associated settings
Type of insulin pump and associated settings
Sequence containing the time and size of each
meal during the simulation
Unique parameters for the patient profile
Beginning time for the simulation
Random number generator seed used for noise
in sensor readings, etc.
Insulin dose to give to the patient for each step

Design and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

Figure 3: Typical APS Control Structure (Left) and OpenAPS Architecture and Input/Output (Right).

ğ‘‘ğ¼ğ‘ ğ‘ (ğ‘¡)
ğ‘‘ğ‘¡

= ğ‘˜ğ‘ ğ‘ğ¼ğ‘ ğ‘ (ğ‘¡) + ğ¼ğ· (ğ‘¡)

(11)

Other variables in the above equations are constant rate param-
eters that are part of the patient profile. This model was improved
in 2013 by implementing the notion that insulin-dependent utiliza-
tion increases non-linearly when glucose decreases below a certain
threshold. Similar to the Glucosym simulator, the UVA-Padova sim-
ulator also uses the minimal glucose model to couple insulin action
on glucose utilization and production. Other parameters required
by the UVA-Padova simulator to run regularly are listed in Table 4.
The two glucose simulators integrated with the APS testbed
could also handle a single meal scenario for the virtual patient
(VP) population, which is challenging for regulating BG in Type
1 diabetes because of unexpected human activities (e.g., meals or
exercises) and patient variability (inter-patient and intra-patient).

3.2 APS Controllers
We integrate two typical control algorithms into the APS testbed: a
PID-based OpenAPS controller and a Basal-Bolus controller.

OpenAPS is an advanced open-source control software used in
the diabetes DIY community [63] that has comparable results with
more rigorously developed and tested AP systems for glycaemic
control [10] and is far safer than standard pump/CGM therapy with
no reports of severe hypo- or hyperglycemic events [62].

The OpenAPS adjusts the insulin delivery of an infusion pump
to automatically keep the BG level of the diabetic patient within a

Table 5: Input Parameters of OpenAPS.

Input
Settings
BG targets
Insulin Sensitiv-
ity
Basal profile
Preferences
Pump history
Clock
Temp_basal
Glucose

Description
Various settings specific to the pump
High/low glucose targets set up in the pump
The expected decrease in BG as a result of one
unit of insulin
The basal rates that are set up in the pump
User-defined preferences
Last 5 hours data directly from the pump
Date and time that is set on the pump
Current insulin delivery rate set up in pump
Glucose level sensed by CGM

safe range. The internal architecture and necessary input-output
connections of OpenAPS are shown in Fig. 3. The description of
input parameters is listed in Table 5. The shaded region indicates
the OpenAPS controller, and the "File Storage" section reflects the
behavior of the insulin pump. The functionality of OpenAPS can
be divided into three processes. The Get_profile process accepts
pump settings, target BG (BGT), insulin sensitivity, basal profile,
and preferences as inputs and creates a profile required to calculate
both IOB and recommended insulin delivery. The Calculate_iob
process gets profile, clock, and pump history as input and calculates
IOB. Finally, the Determine_basal process accepts the profile, IOB,
BG, and current insulin delivery (temp_basal) and calculates the
suggested insulin delivery to the patient.

More specifically, OpenAPS collects the previously delivered
insulin amount, combined with the duration of the activity, and it
calculates the net IOB. Using the glucose sensor readings, OpenAPS
then calculates the eventual BG using the following equation [5]:

ğ‘’ğ‘£ğ‘’ğ‘›ğ‘¡ğ‘¢ğ‘ğ‘™ğµğº = ğ¶ğ‘¢ğ‘Ÿğ‘Ÿğ‘’ğ‘›ğ‘¡ğµğº âˆ’ ğ¼ğ‘†ğ¹ âˆ— ğ¼ğ‘‚ğµ + ğ‘‘ğ‘’ğ‘£ğ‘–ğ‘ğ‘¡ğ‘–ğ‘œğ‘›

(12)

where ğ¶ğ‘¢ğ‘Ÿğ‘Ÿğ‘’ğ‘›ğ‘¡ğµğº is the current BG, ğ¼ğ‘†ğ¹ is the Insulin Sensi-
tivity Factor, and ğ¸ğ‘£ğ‘’ğ‘›ğ‘¡ğ‘¢ğ‘ğ‘™ğµğº is the estimated BG by the end of

cancel any temp basal;

Algorithm 1: OpenAPS Algorithms
1 if BG is rising, but ğ‘’ğ‘£ğ‘’ğ‘›ğ‘¡ğ‘¢ğ‘ğ‘™ğµğº < ğµğº_ğ‘‡ ğ‘ğ‘Ÿğ‘”ğ‘’ğ‘¡ then
2
3 else if BG is falling, but ğ‘’ğ‘£ğ‘’ğ‘›ğ‘¡ğ‘¢ğ‘ğ‘™ğµğº > ğµğº_ğ‘‡ ğ‘ğ‘Ÿğ‘”ğ‘’ğ‘¡ then
4
5 else if ğ‘’ğ‘£ğ‘’ğ‘›ğ‘¡ğ‘¢ğ‘ğ‘™ğµğº > ğµğº_ğ‘‡ ğ‘ğ‘Ÿğ‘”ğ‘’ğ‘¡ then
6

cancel any temp basal;

cancel 30min temp basal;
if recommended temp>existing basal then

7

8

9

10

11

12

issue the new high temp basal;

else if recommended temp<existing basal then

issue the new high temp basal;
else if 0 temp for >30m is required then

extend zero temp by 30 min;

end

13
14 end

5

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

X. Zhou, M. Kouzel, H. Ren, H. Alemzadeh.

Table 6: Input Parameters of Basal-Bolus Controller.

Input
CGM
CHO

BW
ğ‘¢2ğ‘ ğ‘ 
CR
CF (ISF)

Description
Continuous glucose monitor sensor reading
Grams of carbohydrates consumed by patient
(if meal occurred at current step)
Patientâ€™s body weight
Steady state insulin rate per kilogram
Insulin to carbs ratio
Insulin correlation (sensitivity) factor[27]

current insulin delivery. A deviation term is also added, which is
the difference in BG prediction based on purely insulin activity.

While the current BG is below a threshold value, OpenAPS con-
tinues to issue a temporary zero insulin delivery until the BG rises.
Otherwise, OpenAPS determines whether the glucose values rise
or fall more than expected. In that case, it performs the course of
actions shown in Algorithm 1 [5].

Basal-Bolus regimens are widely used in insulin pumps [16,
17, 43]. Basal provides a constant supply of insulin to bring down
high resting blood glucose levels. Bolus insulin, on the other hand,
has a much more powerful but shorter-lived effect on blood sugar,
making it an ideal supplement for people with diabetes to take after
meals and in moments of extremely high blood sugar.

In the Basal-Bolus (BB) Controller, the constant supply of basal

in Table 6. This bolus is the units of insulin to be delivered, so it
is divided by the length of a simulation step to become units of
insulin per minute.

3.3 Closed Loop Simulation
Fig. 3 shows an example of the closed-loop simulation process by
integrating the Glucosym simulator and OpenAPS control software.
At each control loop, the estimated glucose value is updated and
reported to the APS controller, based on which the controller calcu-
lates the recommended insulin dosage and sends it to the glucose
simulator. The insulin amount is divided by 60 to convert the units
from ğ‘ˆ ğ‘›ğ‘–ğ‘¡/â„ğ‘œğ‘¢ğ‘Ÿ to ğ‘ˆ ğ‘›ğ‘–ğ‘¡/ğ‘šğ‘–ğ‘›ğ‘¢ğ‘¡ğ‘’ to make OpenAPS and Glucosym
work appropriately in a closed loop. The glucose value updates
every five minutes (this is the value normally set by CGM [19]),
and so does the control action.

In the UVA-Padova simulation, the CGM sensor is simulated by
looking up the subcutaneous glucose state variable in the patient
model, applying noise, and clipping it to be within the range of
values an actual CGM sensor can return. Similarly, the simulated
pump receives a basal and a bolus input from the controller, converts
the values into the appropriate units (ğ‘ğ‘šğ‘œğ‘™/ğ‘šğ‘–ğ‘›), and clips the
inputs to be within the real range of the insulin pump before sending
the values to the patient model. These calls occur once per minute
(5 times per environment step).

insulin is determined as shown in Equation 13 [70]:

ğ¼ğ‘ğ‘ğ‘ ğ‘ğ‘™ =

ğ‘¢2ğ‘ ğ‘  Â· ğµğ‘Š
6000

(13)

where ğ‘¢2ğ‘ ğ‘  is the patientâ€™s steady-state insulin rate per kg and ğµğ‘Š
is body weight (kg), meaning basal insulin is in units of insulin per
minute. Bolus insulin is determined by Equation 14 when a meal
has occurred (otherwise, no bolus is given) [70]:

ğ¼ğ‘ğ‘œğ‘™ğ‘¢ğ‘  =

ï£±ï£´ï£´ï£²
ï£´ï£´
ï£³

ğ¶ğ»ğ‘‚
ğ¶ğ‘…
ğ¶ğ»ğ‘‚
ğ¶ğ‘… +

ğµğº âˆ’ ğµğºğ‘‡
ğ¶ğ¹

if ğµğº â‰¤ 150

if ğµğº > 150

(14)

where ğ¶ğ»ğ‘‚ is the mealâ€™s size in grams of carbohydrates, ğµğº is the
CGM sensor reading, ğµğºğ‘‡ is the target blood glucose of 120, ğ¶ğ‘… is
the insulin to carbs ratio, and ğ¶ğ¹ is the correlation factor. The list of
input parameters of the Basal-Bolus controller is also summarized

The Basal-Bolus controller uses additional patient-specific pa-
rameters to calculate insulin doses. For the basal insulin, it requires
the patientâ€™s body weight and steady-state insulin rate. For the
bolus dose, it uses the patientâ€™s insulin to carbs ratio (CR) and corre-
lation factor (CF). Both CR and CF can be calculated from the Total
Daily Dose (TDD) of insulin needed, which in turn is calculated
from body weight, as shown in the following equations [12, 61]:
ğ‘‡ ğ·ğ· = 0.55 Â· ğµğ‘Š
ğ¶ğ‘… = 450/ğ‘‡ ğ·ğ·
ğ¶ğ¹ = 1700/ğ‘‡ ğ·ğ·

(17)

(15)

(16)

3.4 Adverse Event Simulator
After a medical device, such as a CGM, insulin pump, or APS, is
distributed in the market, the FDA monitors reports of adverse

Table 7: Example Recall Event Reports That Involved Device and Software Malfunctions.

Recall ID

Summary Recall Description

Z-1074-2013

Z-1034-2015

Z-1734-2015

Z-1359-2012

Z-0929-2020

Z-1562-2020

Z-2165-2020

Z-1772-2021

The blood glucose meter will shut off and revert to set up mode at glucose values above 1023 instead of displaying
EXTREME HIGH GLUCOSE.
Calibration factors in the pump are overwritten during a programming step. The force sensor could send a lower signal
value to the pump processor.
If the user does not act upon the E6 and E10 error messages appropriately, insulin delivery will be stopped and, if
unnoticed, may lead to severe hyperglycemia.
An error was discovered in the blood glucose meter software so that the meter turns itself off when a user attempts to
view results in the "Results Log" when the log has 256 or a multiple of 256 items to display.
The mobile receiver can become stuck on the initialization screen when powering on. This will cause patients not to
be able to receive glucose values or alerts
The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely
elevate glucose readings on the CGM.
After the device has been in use for about two months, data processing in the PDM can be slowed such that the Bolus
Calculator fails to accurately subtract the correct amount of IOB before suggesting a bolus amount.
Under certain conditions, a software fault is detected when a large bolus delivery at a quick bolus speed completes. If
the user is unaware of the amount of active insulin and delivers an additional bolus, there is a risk of insulin over
delivery.

6

Device Design

Software Design

Software Design

FDA Determined
Cause
Software Design

Affected
Device
Glucose
Monitor
Insulin
Pump
Insulin
Pump
Glucose
Monitor
Glucose
Monitor
Under Investigation Gluocse
Monitor
Insulin
Pump
Insulin
Pump

Software Design

Software Design

Device Design

Design and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

Table 8: Simulated Fault and Adverse Event Scenarios

Fault Type

Fault Injection Approach

Truncate

Change output variables to zero value [64][13]

Hold

Stop refreshing selected input/output variables [7][13]

Add/
Sub
1 Recall IDs assigned by FDA which are also listed in Table 7.

Add or subtract an arbitrary or particular value
to a targeted variable [7][47]

events and other problems with the device and, when necessary,
alerts health professionals and the public to ensure proper use of
the device and safety of patients [24, 52]. A recall is a voluntary
action that a device manufacturer takes to correct or remove from
the market any medical devices that violate the laws administrated
by the FDA [51]. Recalls are initiated to protect public health and
well-being from devices that are defective or that present health
risks such as disease, injury, or death. In rare cases, if the company
fails to recall a device that presents a health risk voluntarily, the
FDA might issue a recall order to the manufacturer.

FDA regulations also require manufacturers to notify the FDA
of the adverse events, including device malfunctions [54], serious
injuries [55], and deaths [56] associated with medical devices. Not
all reported adverse events lead to recalls. The device manufacturers
and the FDA regularly monitor the adverse event reports to detect
and correct problems in a timely manner.

Table 7 shows example recall events from the FDA database
where malfunctions of the commercially available APS devices
or software were reported. The analysis and simulation of past
recalls and typical adverse event scenarios can help with improv-
ing the design and test of the APS control algorithms and safety
mechanisms and assessing their effectiveness in preventing similar
adverse events [22, 24, 49]. However, it is too expensive and risky
to simulate the adverse event scenarios with the actual patients and
human operators in the loop due to the unacceptable consequences
of adverse events and potential harm to patients.

To better evaluate the resilience of APS control algorithms against
such safety issues, we design an adverse events simulator inte-
grated with the closed-loop simulation. Specifically, we design a
software-implemented fault injection (SWFI) engine (see Fig. 2) that
can automatically select a set of target locations within the APS
software (e.g., variables representing the CGM sensor values and
insulin dose commands) to inject faults (e.g., a zero value (Truncate),
a previous value (Hold), or an arbitrary error value (Add/Sub)) and
activate them under pre-defined trigger conditions and durations to
mimic the typical adverse events listed in Table 8, including hyper-
glycemic (diabetic ketoacidosis) and hypoglycemic events, device
malfunctions, and patient injuries. The adverse event simulator is
an independent module and can be enabled or disabled manually.

4 VALIDITY ASSESSMENT
Fig. 4 summarizes the overall framework for the validity assessment
of the APS testbed. We assess the validity of our testbed using the
publicly-available international diabetes closed-loop trial dataset
(DCLP3 [43]). This dataset is collected from a clinical trial of a
closed-loop system (t:slim X2 with Control-IQ Technology) [43]
for the six-month treatment of 168 diabetic patients aged 14 to

Representative FDA Recalls No. Records
Z-1074-2013, Z-1034-2015,
Z-1734-20151
Z-1359-2012, Z-0929-2020,
Z-1376-2012
Z-1562-2020, Z-2165-2020,
Z-1772-2021

15

7

8

Possible Adverse Events

Device Malfunction/
Hypoglycemia/
Hyperglycemia/
Injury/
Death

71 years old, 112 and 56 of which were, respectively, assigned to
the closed-loop group (CLC) and the control group that used a
sensor-augmented pump (SAP).

To be a valid simulator, the generated data should satisfy the
requirements of relevance, completeness, and balance with respect
to real-world data [59]. We ensure relevance and completeness by
generating similar patient profiles to those in the real clinical trials
(with diverse ages, weights, genders, and medical characteristics)
and representative fault/adverse event scenarios that led to FDA
recalls. We measure balance by comparing the percentage of the
time the simulated and real trajectories are within the range or
contain adverse events.

4.1 Glucose Simulation
To assess the validity of the glucose simulators, we randomly choose
five patientsâ€™ data (each six-month long) from the DCLP3 dataset
and compare their BG trajectories during the clinical trial with the
simulated BG traces generated using the same insulin inputs from
the clinical records at each time step of the simulation. At each
simulation time step, the insulin rate is set to the corresponding
insulin rate at the same time step in the DCLP3 trial dataset. This
means that any differences between the BG traces calculated during
the simulation and the BG traces measured during the DCLP3 trial
are only due to the differences between the simulatorâ€™s patient
model and the actual dynamics of the patientâ€™s body.

However, one challenge in reconstructing each patientâ€™s BG
trajectory is that some parameters for characterizing the patient
profiles in the simulators are not available from the DCLP3 dataset.
To solve this problem, we adopt a system identification method
to estimate the patient model parameters (patient profiles) from
data. We model this problem as the following optimization problem
that minimizes the difference between the BG value trajectory
reconstructed using the derived parameters and the BG trajectory

Figure 4: Overall Framework for Validation of the APS Testbed.

7

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

X. Zhou, M. Kouzel, H. Ren, H. Alemzadeh.

Figure 5: BG Trajectories of a Clinical Trial and a Simulation Trace.

Figure 7: Mean Squared Error of BG values between the Clinical
Trial and Each Simulator.

in the DCLP3 dataset:

ğ‘ğ‘ğ‘Ÿğ‘ğ‘š. = ğ‘ğ‘Ÿğ‘”ğ‘šğ‘–ğ‘›ğ‘ğ‘ğ‘Ÿğ‘ğ‘š.

âˆ‘ï¸

D

ğ‘ .ğ‘¡ .âˆ€ğ‘¡ âˆˆ D

(ğµğºğ‘†ğ‘–ğ‘šğ‘¢ğ‘™ğ‘ğ‘¡ğ‘œğ‘Ÿ âˆ’ ğµğºğ·ğ¶ğ¿ğ‘ƒ 3)

(18)

(19)

ğ¼ ğ· (ğ‘¡)ğ‘†ğ‘–ğ‘šğ‘¢ğ‘™ğ‘ğ‘¡ğ‘œğ‘Ÿ = ğ¼ğ· (ğ‘¡)ğ·ğ¶ğ¿ğ‘ƒ 3
ğµğºğ‘†ğ‘–ğ‘šğ‘¢ğ‘™ğ‘ğ‘¡ğ‘œğ‘Ÿ (ğ‘¡) = ğ‘“ğ‘ğ‘ğ‘Ÿğ‘ğ‘š. (ğ¼ğ· (ğ‘¡ âˆ’ 1))

(20)
where ğ‘“ (Â·) represents the patient model shown in Table 2, ğ¼ ğ· (ğ‘¡) is
the insulin delivery at time step ğ‘¡, and D is the dataset for parameter
estimation. We use the linear regression method for parameter
estimation and learning based on ten days of data for each patient
and the remaining 170 days of data is used to evaluate the validity
of the patient simulators. To reduce the number of parameters
that need to be estimated, we also use known metabolic models
to directly calculate some unknown parameters from data. For
example, the insulin sensitivity factor can be solved by the 1700
rule [12] using the following equation:

ğ¼ğ‘†ğ¹ = 1700/ğ‘‡ ğ·ğ·

(21)

An example of the BG trajectory using the estimated patient
profile and the insulin sequence recorded in the dataset is shown
in Fig. 5. We see that the reconstructed BG trajectory could ap-
proximate the BG values in the clinical trial well in the first 360
minutes but departs from the original trajectory in the last 360
minutes of simulation due to the unpredictable human activity and
carbohydrate input.

We also present the distribution of BG values reconstructed for
all the patient profiles by both the Glucosym simulator and the UVA-
Padova simulator in comparison to the baseline BG distribution
collected in the DCLP3 dataset in Fig. 6. We see that the Glucosym

simulator reconstructs the BG distribution that approximates the
baseline BG distribution from the clinical trial in both the target
range ([70-180] mg/dL) and the high/low BG ranges. On the other
hand, the UVA-Padova simulator with the estimated patient profiles
generates a BG distribution that is more concentrated between
[100-300] mg/dL and does not simulate the extra high/low BG
ranges well. We observe similar results when measuring the mean
squared error of the BG values estimated for each patient profile
using the simulators, as shown in Fig. 7. This might be because the
UVA-Padova uses a more complex dynamic model, and it is more
challenging to estimate the patient profiles.

Our preliminary results indicate that with well-tuned patient
parameters, the integrated simulators could reproduce similar BG
traces from the clinical trial if undergoing the same experimental
scenario (i.e., same carbohydrate amount, insulin boluses, and basal
pattern, given at the same time). The validity of both simulators
is also attested to by other researchers who have access to actual
patient profiles [12, 45], and the fact that the UVA-Padova simulator
has been approved by FDA for pre-clinical testing on animals.

4.2 APS Control
To assess the validity of the two controllers in the testbed, we feed
the BG values from the clinical trial dataset with the same sampling
frequency to the different controllers in the testbed, running in an
open-loop mode, and compare the output insulin doses calculated
by the controllers against the actual pump outputs from the clinical
trial. We test the validity of both the OpenAPS controller and the
Basal-Bolus controller on the closed-loop group (CLC, 112 patients)
and the group that used a sensor-augmented pump (SAP group, 56
patients) for six months.

As shown in Table 9, we calculate the Mean Squared Error (MSE)
between the simulated controller and the actual pump outputs. We
see that the Basal-Bolus produced a much smaller MSE in the SAP
group than the OpenAPS controller and maintained a lower MSE
in the CLC group. The OpenAPS controller uses a different control
algorithm from the pump used in the clinical trial.

Table 9: Insulin Output Comparison Among Each Controller

Figure 6: Distribution of BG Values: Clinical Trial Data vs. Recon-
structed Data by Each Simulator.

Metric

AvgÂ±Std

MSE

8

Group No. Patients Clinical Trial
0.067 Â± 0.061
0.049 Â± 0.004
0.061 Â± 0.051
-
-
-

CLC
SAP
Avg
CLC
SAP
Avg

112
64
168
112
64
168

OpenAPS
0.067 Â± 0.043
0.072 Â± 0.045
0.069 Â± 0.044
4.67E-03
2.51E-03
3.97E-03

Basal-Bolus
0.049 Â± 0.004
0.049 Â± 0.004
0.049 Â± 0.004
4.01E-03
4.74E-06
2.70E-03

100200300400500BG (mg/dL)0.0000.0020.0040.0060.0080.010DensityClinical TrialUVA-Padova SimulatorGlucosym SimulatorDesign and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

Table 10: Comparison of the Outcomes between Closed-loop Simulation and the Clinical Trial

Outcome

Pct. of time with BG in target range of 70 to 180 mg/dL

Clinical Trial Closed-loop11 Closed-loop22
66.18Â±25.56

79.46 Â± 16.68

93.49Â±10.67

Pct. of time with BG>180 mgl/dL

Pct. of time with BG<70 mgl/dL

Pct. of time with BG<54 mgl/dL

32.07Â±25.83

1.75Â±4.67

0.33Â±1.67

3.95Â±7.34

2.56Â±7.06

0.12Â±1.63

20.16 Â± 16.08

0.05 Â± 0.24

0.02 Â± 0.14

1 Glucosym simulator with OpenAPS control software.
2 UVA-Padova simulator with Basal-Bolus controller.

An example of the insulin output comparison of both the Ope-
nAPS controller and the Basal-Bolus controller to the control al-
gorithm used by the pump in the clinical trial is shown in Fig. 8.
We observe that the Basal-Bolus controller can well reproduce the
control actions made by the insulin pump used in the clinical trial,
demonstrating the validity of the integrated controller in match-
ing actual insulin pump control actions. On the other hand, the
OpenAPS controller makes different decisions when the predicted
BG is going outside of the target range of 70 t o180 mg/dL or a
risk of hyperglycemia or hypoglycemia is anticipated. It should
be noted that the OpenAPS controller uses the exact control soft-
ware used by actual diabetic patients. This is consistent with the
observation from previous studies that showed OpenAPS has better
performance than some of the existing commercial pumps [10, 62].

4.3 Closed-loop Simulation
Finally, we run the controllers and simulators together in a closed-
loop mode to assess their performance when automatically regulat-
ing the blood glucose of diabetic patients. For this kind of assess-
ment, we cannot compare the BG readings or the insulin outputs
step by step between the simulation and the clinical trial, as a differ-
ing control action changes the subsequent BG values. Instead, we
adopt a metric that evaluates the primary and secondary outcomes
in diabetes treatment [43] by measuring the percentage of time
that the BG value is inside or outside the target range of 70 to 180
mg/dL.

We randomly select five patients to estimate their profiles and
run both simulators with OpenAPS and Basal-Bolus control soft-
ware, respectively, in a closed-loop using the patient profiles and
other required parameters estimated in Section 4.1-4.2.

Experiment results in Table 10 show that both simulated closed-
loop APS maintain a higher percentage of time with BG inside the

target range than the baseline control system used in the clinical
trial, though the closed-loop system with UVA-Padova simulator
and Basal-Bolus controller has a closer outcome with the clinical
trial as they use a similar control algorithm. We also observe that
the closed-loop system with the Glucosym simulator and OpenAPS
controller software keeps the BG in the target range for 93.49% of
the time on average, demonstrating the advance of this PID-based
control algorithm in diabetes treatment over the regular insulin
therapy with Basal-Bolus control algorithm.

The primary outcomes of each closed-loop APS and the actual
control system in the clinical trial across six months are shown in
Fig. 9. We see that the mean percentage of time with glucose values
within the target range remained at a similar level during the six
months in the clinical trial and both closed-loop simulations.

The closed-loop simulation offers a platform to evaluate or im-
prove different pump algorithms with various patient profiles. For
example, Fig. 10 shows the different decisions made by each control
algorithm at each time step during 12.5 hours of treatment/simulation.
We see that the actual pump from the clinical trial used a fixed basal
rate and thus failed to keep the BG within the target range, resulting
in adverse hyperglycemia. In comparison, the OpenAPS kept the
BG value safe by increasing the insulin infusion when the BG is
predicted to increase quickly and keeping a low insulin dose when
the insulin on board is still at a high level after a large amount
of previous insulin injection. Similarly, the Basal-Bolus controller
with the UVA-Padova simulator issued a higher basal rate to avoid
the BG value increasing too fast. Through such simulation and
comparison, the proposed testbed can help to improve different
control algorithms used in commercial insulin pumps and reduce
patient harm or complaints.

4.4 Adverse Event Simulation
From Table 1 and Table 10, we see that adverse events naturally
happen during clinical trials or home treatment of diabetic patients

Figure 8: An Example of the Insulin Outputs among Each Controller
Given the Same Glucose Readings.

Figure 9: Percentage of Time with BG in the Target Range of 70 to
180 mg/dL for Clinical Train and Two Closed-loop APS.

9

123456Month020406080100Pct. of Time with BG in Target RangeGlucosym&OpenAPSUVA-Padova&Basal-BolusClinical TrialCHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

X. Zhou, M. Kouzel, H. Ren, H. Alemzadeh.

Figure 10: Comparison of BG and Insulin Rate between a Clinical Trial and the Closed-loop Simulation.

with APS due to device malfunctions or control software defects.
However, it is expensive or risky for the manufacturers to test
and improve the control algorithms through experiments on actual
patients within realistic environments. The proposed closed-loop
simulation offers an alternative way to evaluate the effectiveness
of different control algorithms with actual patient profiles. How-
ever, the rate of adverse events in the closed-loop simulation is
too low to evaluate the resilience of the target control algorithm
comprehensively. Therefore, the adverse event simulator proposed
in Section 3.4 was used to simulate the following scenarios: hy-
perglycemic adverse events (diabetic ketoacidosis), hypoglycemic
events, malfunction of the device, and injury of patients.

We run 882 simulations (14 fault scenarios, as Add/Sub includes
multiple sub-scenarios, times 9 random start times and durations
times 7 initial BG values), and each simulation includes 12.5 hours
of sensor data and insulin outputs after a meal with different car-
bohydrate inputs. An example of the BG trajectory with a fault
injected starting at 400 minutes to simulate a CGM sensor read-
ing malfunction is shown in Fig. 11. We see that the controller
increased the insulin injection significantly based on the erroneous
CGM readings while the BG value was not high, which further
decreased the BG value under 50 mg/dL and resulted in a severe
hypoglycemic event (marked by the red region in Fig. 11).

Our simulation generates two and a half years of data for 20 dia-
betes patients with different types of adverse events. The percentage

of adverse events in the Glucosym simulator and UVA-Padova sim-
ulator are 33.9% and 39.3%, respectively (see Fig. 12). The generated
synthetic dataset is available on Github [https://github.com/UVA-
DSA/APS_TestBed].

5 RELATED WORK
MCPS Testbeds: Testbeds are used in place of time- and resource-
intensive clinical trials, so development has gravitated towards
systems that affect the most critical organs. For instance, heart
testbeds have been constructed for pacemaker validation [73] and
cardiovascular interventions [71]. Robotic surgery testbeds have
also been made for MRI-guided biopsy [65], endovascular surgery
[29], and reconstructive surgeries in the hand [26]. In-silico trials
of an insulin control algorithm are developed recently to facilitate
research on APS [68, 68]. To the best of our knowledge, this paper
is the first to develop an open-source closed-loop testbed for APS
with real-world controllers, physical simulators of an extended set
of patient profiles, and a realistic adverse event simulator.

Glucose Simulators: The use of simulators is vital in the devel-
opment of APS. A glucose minimum model, a simple mathematical
model for glucose levels, was first proposed in 1970 [36]. The UVA-
Padova simulator [11] was the first APS simulator to be approved
by the FDA in 2008 as a substitute for animal testing. A second sim-
ulation developed by a group at Cambridge University was released
soon after in 2010, specifically targeted toward closed-loop APS
simulation and virtual patient modeling [33]. The UVA-Padova was
updated in 2014 [12] to improve the glucose kinetics model during
hypoglycemia as well as incorporate glucagon kinetics and was
accepted by the FDA as a substitute for certain preclinical trials.
Glucosym, an open-source APS simulator, was released in 2017 to

Figure 11: An Example of Simulated Hypoglycemic Adverse Event
due to Fault Injection.

Figure 12: Success Rate of the Fault Injection Experiments in Sim-
ulating Low BG Hazard (H1) and High BG Hazard (H2), which may
Result in Hypoglycemic or Hyperglycemic Adverse Event.

10

0200400600800100050100150200(mg/dL)BG1012(Unit,mg/dL/min)Insulin_rateIOB02004006008001000Time (minute)0.00.51.01.5  Fault injectionHazardsDesign and Validation of an Open-Source Closed-Loop Testbed for Artificial Pancreas Systems

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

widen the availability of closed-loop APS simulation and testing
[66]. In 2019, a group at the Oregon Health and Science University
(OHSU) published an APS simulator based on a similar glucoregu-
latory model as the Cambridge simulator but with different insulin
kinetics [35]. Our work differentiates from these previous works
by integrating two advanced control software with the state-of-
the-art simulators into a closed-loop APS testbed and proposing
an optimization method to estimate real patient profiles for the
closed-loop simulation.

Safety Evaluation of APS: Many previous works have also
focused on evaluating the safety of APS control software, such
as safety and effectiveness evaluation of insulin pump therapy in
children and adolescents with Type 1 diabetes [2, 30], safety and
efficacy review of commercial and emerging hybrid closed-loop
systems [25, 58], generic safety requirements for developing safe
insulin pump software [50] and insulin pump software certification
[48], or safety evaluation of do-it-yourself APS [69]. However, most
of these works relied on high-risk clinical tests or were not able to
assess the resilience of tested insulin pumps against adverse events.
In this paper, we integrate an adverse simulator into the closed-loop
APS testbed, which could help with the evaluation of different APS
control algorithms and safety mechanisms in preventing adverse
events while avoiding actual harm to the patients.

6 CONCLUSION
Using two state-of-the-art glucose simulators, we develop a testbed
for evaluating the performance of the control algorithms and safety
features in APS. We assess the validity of the simulator by reverse-
engineering the profiles of patients in a real clinical trial and demon-
strating that the BG traces generated by each simulator are func-
tionally the same as the BG traces from the trial. We also show the
testbedâ€™s utility for closed-loop simulation by implementing two
control algorithms to regulate the glucose levels of virtual patients.
To push the APS to its limit, we embed a novel fault injection engine
based on real FDA recalls into the testbed so performance can be
evaluated in even the most hostile scenarios.

As research turns toward adopting more advanced data-driven
methods like machine learning for the design of control algorithms,
the proposed testbed and other in silico testing strategies will be
essential for both final product evaluation and sourcing large quan-
tities of high-quality data. This testbed can also be used to further
develop personalized treatments by tailoring control algorithms
to individual or similar patient profiles and to help diabetic pa-
tients understand their treatments by modeling their physiological
dynamics. In future work, our testbed could be improved by devel-
oping more accurate estimation methods for patient profiles and
incorporating meal and activity models and simulators.

ACKNOWLEDGMENT
This work was partially supported by the Commonwealth of Vir-
ginia under Grant CoVA CCI: C-Q122-WM-02 and by the National
Science Foundation (NSF) under Grant No. 2146295.

REFERENCES
[1] Richard N. Bergman, Diane T. Finegood, Marilyn Ader. 1985. Assessment of

Insulin Sensitivity in Vivo. Endocrine Reviews 6(1), 45â€“86.

11

[2] Ahlam Alotaibi, Reem Al Khalifah, and Karen McAssey. 2020. The efficacy and
safety of insulin pump therapy with predictive low glucose suspend feature in
decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic
review and meta-analysis. Pediatric Diabetes 21, 7, 1256â€“1267.

[3] Mark A Atkinson, George S Eisenbarth, and Aaron W Michels. 2014. Type 1

diabetes. The Lancet 383, 9911, 69â€“82.
[4] Tandem Diabet Care. 2022. Basal-IQ.

providers/products/basal-iq

https://www.tandemdiabetes.com/

[5] OpenAPS community. 2017. Understanding the determine-basal logic. Retrieved

June 3, 2021 from https://openaps.readthedocs.io/en/latest/

[6] Harry Emerson, Matt Guy, and Ryan McConville. 2022. Offline Reinforcement
Learning for Safer Blood Glucose Control in People with Type 1 Diabetes. Technical
Report. arXiv.

[7] Alvaro A. CÃ¡rdenas, Saurabh Amin, Lin Zong-Syun, et al. 2011. Attacks against
process control systems: risk assessment, detection, and response. In the 6th ACM
Symposium on Information, Computer and Communications Security. 355â€“366.
[8] Aaron Bray, Jeffrey B. Webb, Andinet Enquobahrie, et al. 2019. Pulse Physiol-
ogy Engine: an Open-Source Software Platform for Computational Modeling of
Human Medical Simulation. SN Comprehensive Clinical Medicine 1, 5, 362â€“377.
[9] Andrea Facchinetti, Simone Del Favero, Giovanni Sparacino, et al. 2014. Modeling
the Glucose Sensor Error. IEEE Transactions on Biomedical Engineering 61, 620â€“
629.

[10] Andreas Melmer, Thomas ZÃ¼ger, Dana M Lewis, et al. 2019. Glycaemic control in
individuals with type 1 diabetes using an open source artificial pancreas system
(OpenAPS). Diabetes, Obesity and Metabolism 21, 10, 2333â€“2337.

[11] Boris P. Kovatchev, Marc Breton, Chiara Dalla Man, et al. 2009. In Silico Preclinical
Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. Journal of
Diabetes Science and Technology 3, 1, 44â€“55.

[12] Chiara Dalla Man, Francesco Micheletto, Dayu Lv, et al. 2014. The UVA/PADOVA
Type 1 Diabetes Simulator. Journal of Diabetes Science and Technology 8, 1, 26â€“34.
[13] Charrise M Ramkissoon, Brian Aufderheide, B Wayne Bequette, et al. 2017. A
review of safety and hazards associated with the artificial pancreas. IEEE reviews
in biomedical engineering 10, 44â€“62.

[14] Divya Govindaraju, RR Shree, S Priyanka, et al. 2022. Event Detection and Control
of Blood Glucose Levels Using Deep Neural Network. In Artificial Intelligence
and Evolutionary Computations in Engineering Systems. Springer, 235â€“245.
[15] David M. Maahs, Peter Calhoun, Bruce A. Buckingham, et al. 2014. A randomized
trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.
Diabetes Care 37, 7, 1885â€“1891.

[16] Elena Chertok Shacham, Hila Kfir, Naama Schwartz, et al. 2018. Glycemic control
with a basal-bolus insulin protocol in hospitalized diabetic patients treated with
glucocorticoids: a retrospective cohort. BMC Endocr Disord 18(75), 1472â€“6823.
[17] Fraser Cameron, B Wayne Bequette, Darrell M Wilson, et al. 2011. A Closed-Loop
Artificial Pancreas Based on Risk Management. Journal of Diabetes Science and
Technology 5, 2, 368â€“379.

[18] Farooq Gessa, Philip Asare, Aaron Bray, et al. 2019. Towards a test and validation
framework for closed-loop physiology management systems for critical and
perioperative care. ACM SIGBED Review 16, 2, 31â€“40.

[19] Giuseppe Fico, Liss HernÃ¡ndez, Jorge Cancela, et al. 2017. Exploring the frequency
domain of continuous glucose monitoring signals to improve characterization
of glucose variability and of diabetic profiles. Journal of diabetes science and
technology 11, 4, 773â€“779.

[20] Homa Alemzadeh, Catello Di Martino, Zhanpeng Jin, et al. 2012. Towards re-
siliency in embedded medical monitoring devices. In IEEE/IFIP International
Conference on Dependable Systems and Networks Workshops. 1â€“6.

[21] Homa Alemzadeh, Daniel Chen, Xiao Li, et al. 2016. Targeted Attacks on Tele-
operated Surgical Robots: Dynamic Model-Based Detection and Mitigation. In
2016 46th Annual IEEE/IFIP International Conference on Dependable Systems and
Networks (DSN). 395â€“406.

[22] Homa Alemzadeh, Daniel Chen, Zbigniew Kalbarczyk, et al. 2015. A software
framework for simulation of safety hazards in robotic surgical systems. In Special
Issue on Medical Cyber Physical Systems Workshop, Vol. 12. SIGBED Review.
[23] Homa Alemzadeh, Jaishankar Raman, Nancy Leveson, et al. 2016. Adverse events
in robotic surgery: a retrospective study of 14 years of FDA data. PloS one 11, 4,
e0151470.

[24] Homa Alemzadeh, Ravishankar K Iyer, Zbigniew Kalbarczyk, et al. 2013. Analysis
of safety-critical computer failures in medical devices. IEEE Security & Privacy
11, 4, 14â€“26.

[25] Irl B Hirsch, Jill Abelseth, Bruce W Bode, et al. 2008. Sensor-augmented insulin
pump therapy: results of the first randomized treat-to-target study. Diabetes
technology & therapeutics 10, 5, 377â€“383.

[26] James A. Tigue, W. Bradford Rockwell, K. Bo Foreman, et al. 2020. Simulating
Tendon Shortening During Flexor Tendon Repair Surgery Using A Biomechanical
Model and Robotic Testbed. In 2020 8th IEEE RAS/EMBS International Conference
for Biomedical Robotics and Biomechatronics (BioRob). 193â€“198.

[27] John Walsh, Ruth Roberts, Timothy S. Bailey, et al. 2018. Bolus Advisors: Sources
of Error, Targets for Improvement. Journal of Diabetes Science and Technology
12(1), 190â€“198.

CHASEâ€™ 22, November 17â€“19, 2022, Washington, DC, USA

X. Zhou, M. Kouzel, H. Ren, H. Alemzadeh.

[28] Kamuran Turksoy, Lauretta T. Quinn, Elizabeth Littlejohn, et al. 2014. An In-
tegrated Multivariable Artificial Pancreas Control System. Journal of Diabetes
Science and Technology 8, 3, 498â€“507.

[29] Lennart Karstensen, Torben PÃ¤tz, Franziska Mathis-Ullrich, et al. 2021. Facile
Testbed for Robotic X-ray based Endovascular Interventions. Current Directions
in Biomedical Engineering 7, 1, 121â€“125.

[30] Leslie P Plotnick, Loretta M Clark, Frederick L Brancati, et al. 2003. Safety and
effectiveness of insulin pump therapy in children and adolescents with type 1
diabetes. Clinical Diabetology 4, 3, 245â€“252.

[31] Marzia Cescon, Daniel J DeSalvo, Trang T Ly, et al. 2016. Early detection of
infusion set failure during insulin pump therapy in type 1 diabetes. Journal of
diabetes science and technology 10, 6, 1268â€“1276.

[32] Marc D. Breton, Lauren G. Kanapka, Roy W. Beck, et al. 2020. A Randomized
Trial of Closed-Loop Control in Children with Type 1 Diabetes. The New England
Journal of Medicine 383, 9, 836â€“845.

[33] Malgorzata E. Wilinska, Ludovic J. Chassin, Carlo L. Acerini, et al. 2010. Simula-
tion Environment to Evaluate Closed-Loop Insulin Delivery Systems in Type 1
Diabetes. Journal of Diabetes Science and Technology 4, 1, 132â€“144.

[34] Muhammad Taimoor Khan, Martin Pinzger, Dimitrios Serpanos, et al. 2020.
Runtime Protection of Real-time Critical Control Applications against Known
Threats. IEEE Design & Test 37, 6, 88â€“95.

[35] Navid Resalat, Joseph El Youssef, Nichole Tyler, et al. 2019. A statistical vir-
tual patient population for the glucoregulatory system in type 1 diabetes with
integrated exercise model. PLOS ONE 14, 7.

[36] PA Insel, KJ Kramer, RS Sherwin, et al. 1974. Modeling the insulin-glucose system

in man. Fed Proc 33, 7, 1865â€“8.

[37] Po-Liang Wu, Dhashrath Raguraman, Lui Sha, et al. 2014. A Treatment Validation
Protocol for Cyber-Physical-Human Medical Systems. In 2014 40th EUROMICRO
Conference on Software Engineering and Advanced Applications. 183â€“190.
[38] Qingnan Sun, Marko V Jankovic, Lia Bally, et al. 2018. Predicting blood glucose
with an lstm and bi-lstm based deep neural network. In 2018 14th symposium on
neural networks and applications (NEUREL). IEEE, 1â€“5.

[39] Rayhan A Lal, Laya Ekhlaspour, Korey Hood, et al. 2019. Realizing a Closed-Loop
(Artificial Pancreas) System for the Treatment of Type 1 Diabetes. Endocrine
Reviews 40, 6, 1521â€“1546.

[40] Revital Nimri, Natasa Bratina, Olga Kordonouri, et al. 2017. MD-Logic overnight
type 1 diabetes control in home settings: A multicentre, multinational, single
blind randomized trial. Diabetes, Obesity and Metabolism 19, 4, 553â€“561.
[41] R S Sherwin, K J Kramer, J D Tobin, et al. 1974. A Model of the Kinetics of Insulin

in Man. J Clin Invest 53(5), 1481â€“1492.

[42] Roberto Visentin, Enrique Campos-NÃ¡Ã±ez, Michele Schiavon, et al. 2018. The
UVA/Padova type 1 diabetes simulator goes from single meal to single day. Journal
of diabetes science and technology 12, 2, 273â€“281.

[43] Sue A Brown, Boris P Kovatchev, Dan Raghinaru, et al. 2019. Six-month random-
ized, multicenter trial of closed-loop control in type 1 diabetes. New England
Journal of Medicine 381, 18, 1707â€“1717.

[44] Sunil Deshpande, Jordan E. Pinsker, Stamatina Zavitsanou, et al. 2019. Design and
Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smart-
phone App: Interoperable Components with Modular Design for Progressive
Artificial Pancreas Research and Development. Diabetes Technology & Therapeu-
tics 21, 1, 35â€“43.

[45] SS Kanderian, S Weinzimer, G Voskanyan, et al. 2009. Identification of Intraday
Metabolic Profiles during Closed-Loop Glucose Control in Individuals with Type
1 Diabetes. Journal of diabetes science and technology 3, 5, 1047â€“1057.

[46] Sediqeh Samadi, Mudassir Rashid, Kamuran Turksoy, et al. 2018. Automatic
Detection and Estimation of Unannounced Meals for Multivariable Artificial
Pancreas System. Diabetes Technology & Therapeutics 20, 3, 235â€“246.

[47] Xugui Zhou, Anna Schmedding, Haotian Ren, et al. 2022. Strategic Safety-Critical
Attacks Against an Advanced Driver Assistance System. In 2022 52nt Annual
IEEE/IFIP International Conference on Dependable Systems and Networks (DSN).

[48] Yihai Chen, Mark Lawford, Hao Wang, et al. 2013.

Insulin pump software
certification. In International Symposium on Foundations of Health Informatics
Engineering and Systems. Springer, 87â€“106.

[49] Yanchen Xu, Daniel Tran, Yuan Tian, et al. 2019. Analysis of cyber-security
vulnerabilities of interconnected medical devices. In 2019 IEEE/ACM Interna-
tional Conference on Connected Health: Applications, Systems and Engineering
Technologies (CHASE).

[50] Yi Zhang, Raoul Jetley, Paul L Jones, et al. 2011. Generic safety requirements for
developing safe insulin pump software. Journal of diabetes science and technology
5, 6, 1403â€“1419.

[51] U.S. Food and Drug Administration. 2020. Recalls, Corrections and Removals (De-
vices). Retrieved September 29, 2020 from https://www.fda.gov/medical-devices/
postmarket-requirements-devices/recalls-corrections-and-removals-devices

[52] US Food and Drug Administration. 2022. CFR - Code of Federal Regulations Title
21. Retrieved Mar 29, 2022 from https://www.accessdata.fda.gov/scripts/cdrh/
cfdocs/cfcfr/cfrsearch.cfm?fr=312.32

[53] U.S. Food and Drug Administration. 2022. MAUDE - Manufacturer and
Retrieved June 3, 2022 from https://

User Facility Device Experience.

12

www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.cfm

[54] U.S. Food and Drug Administration. 2022. MAUDE Adverse Event Report. Re-
trieved June 3, 2022 from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/
cfMAUDE/Detail.cfm?MDRFOI__ID=2417117

[55] U.S. Food and Drug Administration. 2022. MAUDE Adverse Event Report. Re-
trieved June 3, 2022 from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/
cfMAUDE/Detail.cfm?MDRFOI__ID=2430675

[56] U.S. Food and Drug Administration. 2022. MAUDE Adverse Event Report. Re-
trieved June 3, 2022 from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/
cfMAUDE/detail.cfm?mdrfoi__id=6113784&pc=LZG

[57] U.S. Food and Drug Administration. 2022. Medical Device Recalls. Retrieved June
3, 2022 from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm
[58] Julia Fuchs and Roman Hovorka. 2020. Closed-loop control in insulin pumps for
type-1 diabetes mellitus: safety and efficacy. Expert review of medical devices 17,
7, 707â€“720.

[59] Richard Hawkins, Colin Paterson, and Chiara Picardi et al. 2021. Guidance on

the Assurance of Machine Learning in Autonomous Systems (AMLAS).

[60] Ruiqiang Hu and Chengwei Li. 2015. An Improved PID Algorithm Based on
Insulin-on-Board Estimate for Blood Glucose Control with Type 1 Diabetes.
Computational and Mathematical Methods in Medicine.

[61] Allen B. King and Dana U. Armstrong. 2007. A Prospective Evaluation of Insulin
Dosing Recommendations in Patients with Type 1 Diabetes at Near Normal
Glucose Control: Bolus Dosing. Journal of diabetes science and technology (Online)
1, 1, 42â€“46.

[62] Dana Lewis, Scott Leibrand, and # OpenAPS Community. 2016. Real-world use of
open source artificial pancreas systems. Journal of diabetes science and technology
10, 6, 1411â€“1411.

[63] Dana M Lewis. 2020. Do-it-yourself artificial pancreas system and the OpenAPS

movement. Endocrinology and Metabolism Clinics 49, 1, 203â€“213.

[64] Chunxiao Li, Anand Raghunathan, and Niraj K Jha. 2011. Hijacking an insulin
pump: Security attacks and defenses for a diabetes therapy system. In 2011 IEEE
13th International Conference on e-Health Networking, Applications and Services.
IEEE, 150â€“156.

[65] Evelyn Mendoza and John Peter Whitney. 2019. A Testbed for Haptic and
Magnetic Resonance Imaging-Guided Percutaneous Needle Biopsy. IEEE Robotics
and Automation Letters 4, 4, 3177â€“3183.

[66] Perceptus. 2017. GlucoSym. Retrieved May 3, 2021 from https://github.com/

Perceptus/GlucoSym

[67] Aria Saunders, Laurel H. Messer, and Gregory P. Forlenza. 2019. MiniMed 670G
Hybrid Closed Loop Artificial Pancreas System for the treatment of type 1 diabetes
mellitus: overview of its safety and efficacy. Expert review of medical devices 16,
10, 845â€“853.

[68] Jana Schmitzer, Carolin Strobel, Ronald Blechschmidt, Adrian Tappe, and Heiko
Peuscher. 2022. Efficient closed loop simulation of do-it-yourself artificial pan-
creas systems. Journal of Diabetes Science and Technology 16, 1 (2022), 61â€“69.

[69] Chiara Toffanin, Milos Kozak, Zdenek Sumnik, Claudio Cobelli, and Lenka
Petruzelkova. 2020. In silico trials of an open-source android-based artificial
pancreas: a new paradigm to test safety and efficacy of do-it-yourself systems.
Diabetes technology & therapeutics 22, 2 (2020), 112â€“120.

[70] Phuwadol Viroonluecha, Esteban Egea-Lopez, and Jose Santa. 2021. Evalua-
tion of Blood Glucose Level Control in Type 1 Diabetic Patients Using Deep
Reinforcement Learning.

[71] Gustaaf J. Vrooijink, Hassna Irzan, and Sarthak Misra. 2018. A Beating Heart
Testbed for the Evaluation of Robotic Cardiovascular Interventions. In 2018 7th
IEEE International Conference on Biomedical Robotics and Biomechatronics (Biorob).
1076â€“1082.

[72] Dyanne P Westerberg. 2013. Diabetic ketoacidosis: evaluation and treatment.

American family physician 87, 5, 337â€“346.

[73] Zhihao Jiang, A Connolly, and R Mangharam. 2010. Using the Virtual Heart Model
to validate the mode-switch pacemaker operation. In 2010 Annual International
Conference of the IEEE Engineering in Medicine and Biology. 6690â€“6693.

[74] Xugui Zhou, Bulbul Ahmed, and James H Aylor et al. 2021. Data-driven design
of context-aware monitors for hazard prediction in artificial pancreas systems.
In 2021 51st Annual IEEE/IFIP International Conference on Dependable Systems and
Networks (DSN). IEEE, 484â€“496.

[75] Xugui Zhou, Maxfield Kouzel, and Homa Alemzadeh. 2022. Robustness Testing of
Data and Knowledge Driven Anomaly Detection in Cyber-Physical Systems. 5th
Annual IEEE/IFIP International Conference on Dependable Systems and Networks
Workshop on Dependable and Secure Machine Learning (DSN-DSML) (2022).
[76] Taiyu Zhu, Kezhi Li, and Pantelis Georgiou. 2021. Personalized Dual-Hormone
Control for Type 1 Diabetes Using Deep Reinforcement Learning. In Explainable
AI in Healthcare and Medicine. Vol. 914. Springer International Publishing, Cham,
45â€“53.

